Pfizer Inc PFE:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 02/03/23 EST

44.10

+0.04 (+0.09%)

Volume

1,340,973

44.06

-0.28 (-0.63%)

Volume

22,249,981

52 week range

41.44 - 56.32

Open44.35
Day High44.39
Day Low43.88
Prev Close44.34
52 Week High56.32
52 Week High Date04/11/22
52 Week Low41.44
52 Week Low Date10/11/22

Key Stats

Market Cap247.323B
Shares Out5.61B
10 Day Average Volume28.04M
Dividend1.64
Dividend Yield3.72%
Beta0.63
YTD % Change-14.01

KEY STATS

Open44.35
Day High44.39
Day Low43.88
Prev Close44.34
52 Week High56.32
52 Week High Date04/11/22
52 Week Low41.44
52 Week Low Date10/11/22
Market Cap247.323B
Shares Out5.61B
10 Day Average Volume28.04M
Dividend1.64
Dividend Yield3.72%
Beta0.63
YTD % Change-14.01

RATIOS/PROFITABILITY

EPS (TTM)5.47
P/E (TTM)8.05
Fwd P/E (NTM)11.84
EBITDA (TTM)42.308B
ROE (TTM)35.91%
Revenue (TTM)100.331B
Gross Margin (TTM)65.52%
Net Margin (TTM)31.30%
Debt To Equity (MRQ)39.59%

EVENTS

Earnings Date05/01/2023(est)
Ex Div Date01/26/2023
Div Amount0.41
Split Date-
Split Factor-

Latest On Pfizer Inc

Pro Picks: Watch all of Tuesday's big stock calls on CNBCJanuary 31, 2023CNBC.com
End of the Covid health emergency won't slow FDA review of shots and treatmentsJanuary 31, 2023CNBC.com
Tuesday, Jan. 31, 2023: Cramer buys more of this stock he says is oversoldJanuary 31, 2023CNBC.com
The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billionJanuary 31, 2023CNBC.com
Pfizer beats EPS estimates; stock falls on lower yearly guidanceJanuary 31, 2023CNBC.com

Content From Our Affiliates

SVB Securities Sticks to Its Hold Rating for Pfizer (PFE)February 2, 2023TipRanks
FDA revises EUA for Paxlovid to remove SARS-CoV-2 viral testing requirementFebruary 1, 2023TipRanks
Novavax refuses to refund $700M for COVID shots never delivered, NY Times saysFebruary 1, 2023TipRanks
Pfizer (PFE) Gets a Buy from BMO CapitalFebruary 1, 2023TipRanks
Pfizer (PFE) Gets a Hold from BarclaysFebruary 1, 2023TipRanks

Profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global...

Albert Bourla Ph.D.

Chairman of the Board, Chief Executive Officer

David Denton

Executive Vice President, Chief Financial Officer

Aamir Malik

Executive Vice President, Chief Business Innovation Officer

Lidia Fonseca Ph.D.

Executive Vice President, Chief Digital and Technology Officer

Douglas Lankler

Executive Vice President, General Counsel

Address

235 E 42ND ST

New York, NY

10017-5703

United States

https://www.pfizer.com/

Top Peers

SYM